Details of Disease

General Information of Disease (ID: DISDUXAD)

Disease Name Benign neoplasm
Synonyms
organ system benign neoplasm; benign unclassifiable tumour; cell type benign neoplasm; benign tumor; benign tumour; neoplasm, benign; benign unclassifiable tumor; benign neoplasm (disease); neoplasm (disease), benign; benign neoplasm
Definition
A neoplasm which is characterized by the absence of morphologic features associated with malignancy (severe cytologic atypia, tumor cell necrosis, and high mitotic rate). Benign neoplasms remain confined to the original site of growth and do not metastasize to other anatomic sites.|Editor note: see https://github.com/NCI-Thesaurus/thesaurus-obo-edition/issues/14
Disease Hierarchy
DISTBY9Z: Tumour
DISDUXAD: Benign neoplasm
Disease Identifiers
MONDO ID
MONDO_0005165
MESH ID
D009369
UMLS CUI
C0086692
MedGen ID
39483
SNOMED CT ID
20376005

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 54 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
DKK2 TTST5KX Limited Biomarker [1]
EPHB3 TT5LM7U Limited Genetic Variation [2]
FOLH1 TT9G4N0 Limited Altered Expression [3]
NF2 TTZIK7P Limited Genetic Variation [4]
RHBDF2 TTH1ZOP Limited Biomarker [5]
ABCB1 TT3OT40 Disputed Biomarker [6]
FASN TT7AOUD Disputed Altered Expression [7]
HMGA2 TTSTVM0 Disputed Altered Expression [8]
MSLN TT4RXME Disputed Altered Expression [9]
SST TTWF7UG Disputed Altered Expression [5]
TOP1 TTGTQHC Disputed Biomarker [10]
ADH1A TT5AHZ0 moderate Altered Expression [11]
HDC TTV9GOF moderate Altered Expression [12]
HOXA7 TTMRE4Q moderate Altered Expression [13]
LTF TTSZDQU moderate Therapeutic [14]
SRD5A2 TTT02K8 moderate Genetic Variation [15]
VIPR1 TTCL30I moderate Altered Expression [16]
ATM TTKBM7V Strong Biomarker [17]
CAPN1 TT1WBIJ Strong Therapeutic [18]
CAT TTPS279 Strong Therapeutic [19]
COPS5 TTSTNJR Strong Altered Expression [20]
CSF1R TT7MRDV Strong Biomarker [21]
E2F1 TTASI04 Strong Biomarker [22]
ENOX2 TTUJZRL Strong Biomarker [23]
EPHA2 TTRJB2G Strong Biomarker [24]
F9 TTFEZ5Q Strong Biomarker [25]
GLP1R TTVIMDE Strong Biomarker [26]
GPR55 TTNET8J Strong Biomarker [27]
GSTO1 TTWO3SH Strong Biomarker [28]
HSF1 TTN6STZ Strong Biomarker [29]
ID1 TTBXVDE Strong Biomarker [30]
IL18 TTRICUF Strong Therapeutic [31]
IL2 TTF89GD Strong Therapeutic [32]
KCNH2 TTQ6VDM Strong Biomarker [33]
LCN2 TTKTLAI Strong Therapeutic [34]
LIN28A TTO50LN Strong Biomarker [35]
MELTF TT8OBT3 Strong Biomarker [36]
MUC16 TTC1PS3 Strong Genetic Variation [37]
NACC1 TT4AQ5F Strong Biomarker [38]
NOS3 TTCM4B3 Strong Biomarker [39]
NQO1 TT8XK6L Strong Biomarker [40]
PLAUR TTNOSTX Strong Biomarker [41]
PPARA TTJ584C Strong Biomarker [42]
RPS6KA6 TT3KYWB Strong Altered Expression [43]
SKP2 TT5B2EO Strong Biomarker [44]
SLC5A5 TTW7HI9 Strong Therapeutic [45]
STOML2 TTOI329 Strong Altered Expression [46]
TERT TTQY2EJ Strong Biomarker [47]
TNFRSF10A TT5WLRX Strong Therapeutic [48]
TOP2A TTCGY2K Strong Altered Expression [49]
TRPV1 TTMI6F5 Strong Biomarker [50]
VDR TTK59TV Strong Biomarker [51]
AHR TT037IE Definitive Biomarker [52]
NME1 TTDY8JH Definitive Altered Expression [53]
------------------------------------------------------------------------------------
⏷ Show the Full List of 54 DTT(s)
This Disease Is Related to 6 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
ADH4 DEOCWU3 moderate Altered Expression [11]
ADH6 DE017IC moderate Altered Expression [11]
AKR7A2 DE4G629 moderate Altered Expression [11]
AKR1B10 DEP6GT1 Strong Altered Expression [54]
GSTT1 DE3PKUG Strong Biomarker [55]
NAT1 DE7OAB3 Strong Biomarker [56]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
This Disease Is Related to 70 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ABI1 OT5H4M62 Limited Altered Expression [57]
CCNG1 OT17IA9L Limited Altered Expression [58]
HTRA2 OTC7616F Limited Altered Expression [59]
HTRA3 OTXJ0H4X Limited Altered Expression [59]
ING5 OTRNNSFM Limited Altered Expression [60]
KIF1A OT3JVEGV Limited Biomarker [61]
MED15 OT0D0JVD Limited Altered Expression [62]
NDUFAB1 OTF906UR Limited Biomarker [63]
RAB40AL OTZWO8A5 Limited Biomarker [61]
RAP1GAP OTC31ONQ Limited Altered Expression [64]
RGS5 OTUY0Q2I Limited Biomarker [65]
SGTA OTKOJ3JB Limited Biomarker [66]
SMARCB1 OT2LP7LJ Limited Genetic Variation [67]
SS18 OTDKHN1E Limited Genetic Variation [68]
THSD7A OT7249HH Limited Biomarker [69]
BRCA1 OT5BN6VH Disputed Biomarker [70]
AQP6 OTXS6UYY moderate Altered Expression [71]
CBX4 OT4XVRRF moderate Genetic Variation [15]
ELAC2 OTY3BOF6 moderate Genetic Variation [15]
FBLN1 OT5MHHOP moderate Altered Expression [72]
KAT2A OTN0W2SW moderate Biomarker [73]
KLK15 OT7BVG17 moderate Altered Expression [74]
P2RX6 OT1FNTXA moderate Altered Expression [75]
RAB40A OT7JMR2K moderate Biomarker [61]
REEP5 OTZU4TJI moderate Genetic Variation [76]
SEMA3F OTQFMS8S moderate Biomarker [77]
SRSF3 OTOFT707 moderate Altered Expression [78]
STIP1 OT7TXLOX moderate Altered Expression [79]
ADAM12 OTZKOTDB Strong Altered Expression [80]
APOBEC3A OTYO6F5P Strong Biomarker [81]
APOBEC3B OTHLNI51 Strong Biomarker [81]
ARHGAP45 OTL86FEQ Strong Biomarker [82]
ATF2 OTNIZPEA Strong Biomarker [83]
BIRC6 OTCQJAB0 Strong Biomarker [84]
CCDC6 OTXRQDYG Strong Biomarker [25]
CENPF OT7AG0SW Strong Altered Expression [85]
CITED2 OT812TV7 Strong Biomarker [86]
CLIC4 OT6KTPKD Strong Biomarker [87]
CNTN4 OTULXVE0 Strong Altered Expression [88]
COX8A OTU0NR39 Strong Biomarker [89]
CUL1 OTXPE1UZ Strong Altered Expression [90]
DLC1 OTP8LMCR Strong Biomarker [91]
DNAJC10 OTD2EG0R Strong Therapeutic [92]
ERCC1 OTNPYQHI Strong Posttranslational Modification [93]
EXT2 OT8IR5QN Strong Genetic Variation [94]
FLOT1 OT0JPPJZ Strong Biomarker [95]
GPX3 OT6PK94R Strong Biomarker [96]
HOXD8 OTJ5H7AT Strong Altered Expression [97]
HPR OTXSC9UB Strong Biomarker [98]
KDM6A OTZM3MJJ Strong Biomarker [99]
LIN28B OTVWP0FN Strong Biomarker [35]
LMX1A OTEEYD5L Strong Biomarker [100]
LTBP2 OTS88GSD Strong Altered Expression [101]
OCLN OTSUTVWL Strong Biomarker [102]
PAX1 OT0Y3MIM Strong Biomarker [100]
PDIA3 OTHPQ0Q3 Strong Therapeutic [92]
PLAG1 OTT9AJQY Strong Biomarker [103]
PLEKHS1 OT1ZGH1K Strong Biomarker [47]
PPP2R1B OTFIHQGD Strong Genetic Variation [104]
SCG2 OTXWUQQL Strong Biomarker [105]
SEMA4F OTVP97ZV Strong Altered Expression [106]
SEMG2 OTK525XE Strong Biomarker [105]
SOX1 OTVI1RAR Strong Genetic Variation [100]
SRF OTW18FQN Strong Therapeutic [107]
SSX2 OT2Z6RLL Strong Biomarker [68]
SYTL2 OTUIOWKL Strong Altered Expression [46]
TAS2R38 OTX5MM36 Strong Biomarker [25]
TBRG1 OTMV5L8H Strong Altered Expression [108]
TRIM29 OT2DNESG Strong Altered Expression [109]
TSC2 OT47LWI9 Strong Genetic Variation [110]
------------------------------------------------------------------------------------
⏷ Show the Full List of 70 DOT(s)

References

1 Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma.Carcinogenesis. 2012 Dec;33(12):2334-43. doi: 10.1093/carcin/bgs278. Epub 2012 Sep 10.
2 First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.BMC Cancer. 2017 Feb 13;17(1):127. doi: 10.1186/s12885-017-3127-6.
3 Uptake of an Acrochordon Incidentally Detected on 68Ga Prostate-Specific Membrane Antigen PET/CT.Clin Nucl Med. 2017 Jun;42(6):461-462. doi: 10.1097/RLU.0000000000001650.
4 The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.Oncogene. 2016 Jun 30;35(26):3443-53. doi: 10.1038/onc.2015.404. Epub 2015 Nov 9.
5 Diagnostic performance and impact on patient management of (68)Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours.Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1710-1720. doi: 10.1007/s00259-018-3971-x. Epub 2018 Mar 12.
6 P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation.Toxicol In Vitro. 2012 Apr;26(3):435-44. doi: 10.1016/j.tiv.2012.01.014. Epub 2012 Jan 17.
7 Usefulness of immunohistochemical expression analysis of metabolic-related molecules in differentiating between intracranial neoplastic and non-neoplastic lesions.Brain Tumor Pathol. 2013 Jul;30(3):144-50. doi: 10.1007/s10014-012-0120-2. Epub 2012 Oct 12.
8 Combined quantitation of HMGA2 mRNA, microRNAs, and mitochondrial-DNA content enables the identification and typing of thyroid tumors in fine-needle aspiration smears.BMC Cancer. 2019 Oct 28;19(1):1010. doi: 10.1186/s12885-019-6154-7.
9 Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.Tumour Biol. 2018 Oct;40(10):1010428318804937. doi: 10.1177/1010428318804937.
10 New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.Oncology. 2001;61 Suppl 1:14-24. doi: 10.1159/000055387.
11 Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma.Pancreatology. 2009;9(1-2):89-98. doi: 10.1159/000178879. Epub 2008 Dec 12.
12 Differences in the expression of histamine-related genes and proteins in normal human adrenal cortex and adrenocortical tumors.Virchows Arch. 2009 Aug;455(2):133-42. doi: 10.1007/s00428-009-0807-x. Epub 2009 Jul 1.
13 HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.Reprod Sci. 2007 Sep;14(6):605-14. doi: 10.1177/1933719107307781.
14 Therapeutic potential of iron chelators in diseases associated with iron mismanagement.J Pharm Pharmacol. 2006 May;58(5):575-84. doi: 10.1211/jpp.58.5.0001.
15 Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men.Asian Pac J Cancer Prev. 2011;12(3):731-3.
16 Imaging spontaneous MMTVneu transgenic murine mammary tumors: targeting metabolic activity versus genetic products.J Nucl Med. 2010 Jan;51(1):106-11. doi: 10.2967/jnumed.109.069542. Epub 2009 Dec 15.
17 Prenatal exposure to flavonoids: implication for cancer risk.Toxicol Sci. 2011 Mar;120(1):59-67. doi: 10.1093/toxsci/kfq388. Epub 2010 Dec 21.
18 Aspirin Has Antitumor Effects via Expression of Calpain Gene in Cervical Cancer Cells. J Oncol. 2008;2008:285374. doi: 10.1155/2008/285374. Epub 2008 Sep 29.
19 Reactive oxygen species mediate arsenic induced cell transformation and tumorigenesis through Wnt/-catenin pathway in human colorectal adenocarcinoma DLD1 cells.Toxicol Appl Pharmacol. 2011 Oct 15;256(2):114-21. doi: 10.1016/j.taap.2011.07.016. Epub 2011 Aug 11.
20 Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma.J Cancer Res Clin Oncol. 2009 Jul;135(7):951-9. doi: 10.1007/s00432-008-0531-y. Epub 2009 Jan 13.
21 c-fms is present in primary tumours as well as in their metastases in bone marrow.Int J Exp Pathol. 1992 Aug;73(4):527-33.
22 MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance.Theranostics. 2018 Jan 1;8(4):1106-1120. doi: 10.7150/thno.19904. eCollection 2018.
23 Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells. J Cell Biochem. 2010 Aug 15;110(6):1504-11. doi: 10.1002/jcb.22724.
24 Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation.PLoS One. 2011 Mar 30;6(3):e18128. doi: 10.1371/journal.pone.0018128.
25 Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.Thyroid. 2016 Jul;26(7):911-5. doi: 10.1089/thy.2015.0644.
26 On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice.Toxicol Pathol. 2013 Feb;41(2):303-9. doi: 10.1177/0192623312472402.
27 Selective GPR55 antagonism reduces chemoresistance in cancer cells. Pharmacol Res. 2016 Sep;111:757-766. doi: 10.1016/j.phrs.2016.07.013. Epub 2016 Jul 14.
28 Potent and selective inhibitors of glutathione S-transferase omega 1 that impair cancer drug resistance.J Am Chem Soc. 2011 Oct 19;133(41):16605-16. doi: 10.1021/ja2066972. Epub 2011 Sep 27.
29 Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update.Arch Toxicol. 2013 Jan;87(1):19-48. doi: 10.1007/s00204-012-0918-z. Epub 2012 Aug 11.
30 Exit from arsenite-induced mitotic arrest is p53 dependent.Environ Health Perspect. 2006 Sep;114(9):1401-6. doi: 10.1289/ehp.8969.
31 Investigation of PEG-PLGA-PEG nanoparticles-based multipolyplexes for IL-18 gene delivery.J Biomater Appl. 2012 May;26(8):893-916. doi: 10.1177/0885328210384889. Epub 2011 Jan 27.
32 Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.Int J Oncol. 2003 Mar;22(3):691-5.
33 Long-term channel block is required to inhibit cellular transformation by human ether--go-go-related gene (hERG1) potassium channels.Mol Pharmacol. 2014 Aug;86(2):211-21. doi: 10.1124/mol.113.091439. Epub 2014 May 15.
34 Lipocalin 2 antagonizes the proangiogenic action of ras in transformed cells.Mol Cancer Res. 2006 Nov;4(11):821-9. doi: 10.1158/1541-7786.MCR-06-0110.
35 Lin28 promotes transformation and is associated with advanced human malignancies.Nat Genet. 2009 Jul;41(7):843-8. doi: 10.1038/ng.392. Epub 2009 May 31.
36 Pattern of Melanotransferrin Expression in Human Colorectal Tissues: An Immunohistochemical Study on Potential Clinical Application.Anticancer Res. 2015 Dec;35(12):6551-61.
37 Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?.Gynecol Oncol. 2019 Jul;154(1):150-155. doi: 10.1016/j.ygyno.2019.04.006. Epub 2019 Apr 13.
38 Identification of a small-molecule compound that inhibits homodimerization of oncogenic NAC1 protein and sensitizes cancer cells to anticancer agents.J Biol Chem. 2019 Jun 21;294(25):10006-10017. doi: 10.1074/jbc.RA119.007664. Epub 2019 May 17.
39 Tumour maintenance is mediated by eNOS.Nature. 2008 Apr 3;452(7187):646-9. doi: 10.1038/nature06778. Epub 2008 Mar 16.
40 NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues.Cancer Metastasis Rev. 1993 Jun;12(2):103-17. doi: 10.1007/BF00689804.
41 Nicotine stimulates urokinase-type plasminogen activator receptor expression and cell invasiveness through mitogen-activated protein kinase and reactive oxygen species signaling in ECV304 endothelial cells. Toxicol Appl Pharmacol. 2012 Mar 1;259(2):248-56. doi: 10.1016/j.taap.2012.01.002. Epub 2012 Jan 9.
42 Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis.J Biol Chem. 2007 Jun 15;282(24):17685-95. doi: 10.1074/jbc.M701429200. Epub 2007 Apr 3.
43 Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines.Med Oncol. 2016 Feb;33(2):11. doi: 10.1007/s12032-015-0724-6. Epub 2016 Jan 5.
44 Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.Cancer Res. 2008 May 1;68(9):3379-88. doi: 10.1158/0008-5472.CAN-07-6109.
45 Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter.Biochem Biophys Res Commun. 2004 Dec 3;325(1):157-66. doi: 10.1016/j.bbrc.2004.09.219.
46 Expression and clinical significance of SLP-2 in ovarian tumors.Oncol Lett. 2019 May;17(5):4626-4632. doi: 10.3892/ol.2019.10116. Epub 2019 Mar 5.
47 Genome-wide analysis of noncoding regulatory mutations in cancer.Nat Genet. 2014 Nov;46(11):1160-5. doi: 10.1038/ng.3101. Epub 2014 Sep 28.
48 Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.J Clin Oncol. 2009 Sep 10;27(26):4413-21. doi: 10.1200/JCO.2008.21.7422. Epub 2009 Aug 3.
49 Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER-2/neu, and survivin.Ann Surg Oncol. 2012 Jun;19(6):1790-9. doi: 10.1245/s10434-011-2184-3. Epub 2011 Dec 28.
50 TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling. Carcinogenesis. 2011 May;32(5):779-85. doi: 10.1093/carcin/bgr037. Epub 2011 Feb 23.
51 A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.Clin Cancer Res. 1999 Jun;5(6):1339-45.
52 Harmaline and harmalol inhibit the carcinogen-activating enzyme CYP1A1 via transcriptional and posttranslational mechanisms. Food Chem Toxicol. 2012 Feb;50(2):353-62.
53 Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.J BUON. 2007 Jan-Mar;12(1):99-104.
54 Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.Cancer Biomark. 2016;16(1):127-35. doi: 10.3233/CBM-150548.
55 Human health effects of dichloromethane: key findings and scientific issues.Environ Health Perspect. 2015 Feb;123(2):114-9. doi: 10.1289/ehp.1308030. Epub 2014 Oct 17.
56 Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1.Pharmacogenetics. 2001 Aug;11(6):511-20. doi: 10.1097/00008571-200108000-00006.
57 Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.Hum Pathol. 2015 Sep;46(9):1331-40. doi: 10.1016/j.humpath.2015.05.015. Epub 2015 May 30.
58 MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression.J Exp Clin Cancer Res. 2016 Feb 13;35:31. doi: 10.1186/s13046-016-0307-1.
59 Changes in expression of human serine protease HtrA1, HtrA2 and HtrA3 genes in benign and malignant thyroid tumors.Oncol Rep. 2012 Nov;28(5):1838-44. doi: 10.3892/or.2012.1988. Epub 2012 Aug 23.
60 The roles of ING5 expression in ovarian carcinogenesis and subsequent progression: a target of gene therapy.Oncotarget. 2017 Oct 19;8(61):103449-103464. doi: 10.18632/oncotarget.21968. eCollection 2017 Nov 28.
61 Correlation between BRAF mutation and promoter methylation of TIMP3, RAR2 and RASSF1A in thyroid cancer.Epigenetics. 2012 Jul;7(7):710-9. doi: 10.4161/epi.20524. Epub 2012 Jul 1.
62 Clinical and molecular implications of MED15 in head and neck squamous cell carcinoma.Am J Pathol. 2015 Apr;185(4):1114-22. doi: 10.1016/j.ajpath.2014.12.010. Epub 2015 Mar 16.
63 Models of human adamantinomatous craniopharyngioma tissue: Steps toward an effective adjuvant treatment.Brain Pathol. 2017 May;27(3):358-363. doi: 10.1111/bpa.12499.
64 Loss of Rap1GAP in papillary thyroid cancer.J Clin Endocrinol Metab. 2009 Mar;94(3):1026-32. doi: 10.1210/jc.2008-1042. Epub 2008 Dec 9.
65 Pericytes in Sarcomas and Other Mesenchymal Tumors.Adv Exp Med Biol. 2019;1147:109-124. doi: 10.1007/978-3-030-16908-4_4.
66 Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.Horm Cancer. 2013 Jun;4(3):154-64. doi: 10.1007/s12672-013-0135-0. Epub 2013 Feb 27.
67 Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development.Nat Commun. 2017 Aug 21;8(1):300. doi: 10.1038/s41467-017-00346-5.
68 Molecular analyses in the diagnosis and prediction of prognosis in non-GIST soft tissue sarcomas: A systematic review and meta-analysis.Cancer Treat Rev. 2018 May;66:74-81. doi: 10.1016/j.ctrv.2018.04.005. Epub 2018 Apr 22.
69 VEGF-A Links Angiolymphoid Hyperplasia With Eosinophilia (ALHE) to THSD7A Membranous Nephropathy: A Report of 2 Cases.Am J Kidney Dis. 2019 Jun;73(6):880-885. doi: 10.1053/j.ajkd.2018.10.009. Epub 2018 Dec 13.
70 Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.J Pathol. 2004 Feb;202(2):215-23. doi: 10.1002/path.1507.
71 Localisation and expression of aquaporin subtypes in epithelial ovarian tumours.Histol Histopathol. 2011 Sep;26(9):1197-205. doi: 10.14670/HH-26.1197.
72 Elevated expression and altered processing of fibulin-1 protein in human breast cancer.Br J Cancer. 2003 Mar 24;88(6):871-8. doi: 10.1038/sj.bjc.6600802.
73 Expression of PCAF, p300 and Gcn5 and more highly acetylated histone H4 in pediatric tumors.J Exp Clin Cancer Res. 2007 Jun;26(2):269-76.
74 Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression.Prostate. 2013 Aug;73(11):1191-201. doi: 10.1002/pros.22667. Epub 2013 Apr 26.
75 Frequent loss of expression or aberrant alternative splicing of P2XM, a p53-inducible gene, in soft-tissue tumours.Br J Cancer. 1999 Jun;80(8):1185-9. doi: 10.1038/sj.bjc.6690484.
76 The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours.J Pathol. 2002 Apr;196(4):437-44. doi: 10.1002/path.1067.
77 Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas.Hum Pathol. 2006 Nov;37(11):1414-25. doi: 10.1016/j.humpath.2006.04.031. Epub 2006 Sep 28.
78 Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer.Oncogene. 2011 Jan 20;30(3):356-65. doi: 10.1038/onc.2010.426. Epub 2010 Sep 20.
79 Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer.Genes Chromosomes Cancer. 2010 Jul;49(7):585-95. doi: 10.1002/gcc.20769.
80 ADAM12 and ADAM17 gene expression in laser-capture microdissected and non-microdissected breast tumors.Pathol Oncol Res. 2011 Jun;17(2):375-85. doi: 10.1007/s12253-010-9336-9. Epub 2011 Jan 16.
81 An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.Nat Genet. 2015 Sep;47(9):1067-72. doi: 10.1038/ng.3378. Epub 2015 Aug 10.
82 Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. Blood. 2009 Mar 19;113(12):2715-22. doi: 10.1182/blood-2008-05-158956. Epub 2008 Dec 18.
83 Oxidative stress and MAPK involved into ATF2 expression in immortalized human urothelial cells treated by arsenic.Arch Toxicol. 2013 Jun;87(6):981-9. doi: 10.1007/s00204-013-1058-9. Epub 2013 Apr 17.
84 Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil.Gene Ther. 2008 Apr;15(7):484-94. doi: 10.1038/gt.2008.6. Epub 2008 Jan 31.
85 Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors.Oral Oncol. 2005 Aug;41(7):716-22. doi: 10.1016/j.oraloncology.2005.03.008.
86 Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis. J Cell Physiol. 2011 Sep;226(9):2415-28. doi: 10.1002/jcp.22589.
87 CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer.Sci Rep. 2018 Oct 3;8(1):14725. doi: 10.1038/s41598-018-32885-2.
88 Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.J Clin Endocrinol Metab. 2018 Jan 1;103(1):46-55. doi: 10.1210/jc.2017-01314.
89 Radiosurgery treatment is associated with improved facial nerve preservation versus repeat resection in recurrent vestibular schwannomas.Acta Neurochir (Wien). 2019 Jul;161(7):1449-1456. doi: 10.1007/s00701-019-03940-2. Epub 2019 May 26.
90 Cullin1 regulates proliferation, migration and invasion of glioma cells.Med Oncol. 2014 Oct;31(10):227. doi: 10.1007/s12032-014-0227-x. Epub 2014 Sep 9.
91 Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. Oncol Rep. 2011 Jun;25(6):1739-46. doi: 10.3892/or.2011.1239. Epub 2011 Mar 29.
92 Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57. Br J Cancer. 2007 Apr 10;96(7):1062-71. doi: 10.1038/sj.bjc.6603672. Epub 2007 Mar 13.
93 Promoter methylation and expression of DNA repair genes MGMT and ERCC1 in tissue and blood of rectal cancer patients.Gene. 2018 Feb 20;644:66-73. doi: 10.1016/j.gene.2017.10.056. Epub 2017 Nov 17.
94 Familial solitary chondrosarcoma resulting from germline EXT2 mutation. Genes Chromosomes Cancer. 2017 Feb;56(2):128-134. doi: 10.1002/gcc.22419. Epub 2016 Oct 25.
95 Flotillin 1 is differentially expressed in human epithelial ovarian tumors.Neoplasma. 2018;65(4):561-571. doi: 10.4149/neo_2018_170714N483.
96 GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response.Cancer Lett. 2011 Oct 1;309(1):37-45. doi: 10.1016/j.canlet.2011.05.013.
97 Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer.Sci Rep. 2018 Sep 7;8(1):13483. doi: 10.1038/s41598-018-31030-3.
98 Differential heparanase-1 expression in malignant and benign pheochromocytomas.J Surg Res. 2002 Nov;108(1):44-50. doi: 10.1006/jsre.2002.6451.
99 Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.Nat Genet. 2009 May;41(5):521-3. doi: 10.1038/ng.349. Epub 2009 Mar 29.
100 An epigenetic marker panel for screening and prognostic prediction of ovarian cancer.Int J Cancer. 2009 Jan 15;124(2):387-93. doi: 10.1002/ijc.23957.
101 Expression and clinical significance of latent-transforming growth factor beta-binding protein 2 in primary hepatocellular carcinoma.Medicine (Baltimore). 2019 Sep;98(39):e17216. doi: 10.1097/MD.0000000000017216.
102 Epigenetic silencing of occludin promotes tumorigenic and metastatic properties of cancer cells via modulations of unique sets of apoptosis-associated genes. Cancer Res. 2006 Sep 15;66(18):9125-33. doi: 10.1158/0008-5472.CAN-06-1864.
103 Immunohistochemical localization of prostate-specific antigen in benign and malignant breast conditions.Rom J Morphol Embryol. 2005;46(1):41-5.
104 Absence of PPP2R1B gene alterations in primary ovarian cancers.Oncogene. 1999 Nov 4;18(46):6367-9. doi: 10.1038/sj.onc.1203070.
105 Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.J Mol Endocrinol. 2012 Feb 6;48(2):115-27. doi: 10.1530/JME-11-0077. Print 2012 Apr.
106 Semaphorin-plexin signalling genes associated with human breast tumourigenesis.Gene. 2011 Dec 10;489(2):63-9. doi: 10.1016/j.gene.2011.08.024. Epub 2011 Sep 2.
107 Cellular toxicity induced by SRF-mediated transcriptional squelching.Toxicol Sci. 2007 Mar;96(1):83-91. doi: 10.1093/toxsci/kfl172. Epub 2006 Nov 20.
108 NIAM-deficient mice are predisposed to the development of proliferative lesions including B-cell lymphomas.PLoS One. 2014 Nov 13;9(11):e112126. doi: 10.1371/journal.pone.0112126. eCollection 2014.
109 Loss of TRIM29 Alters Keratin Distribution to Promote Cell Invasion in Squamous Cell Carcinoma.Cancer Res. 2018 Dec 15;78(24):6795-6806. doi: 10.1158/0008-5472.CAN-18-1495. Epub 2018 Nov 2.
110 Benign clear cell "sugar" tumor of the lung in a patient with Birt-Hogg-Dub syndrome: a case report.BMC Med Genet. 2016 Nov 21;17(1):85. doi: 10.1186/s12881-016-0350-y.